BACKGROUND: Hepatitis C (HCV) and hepatitis B (HBV) virus infection can lead to serious complications if left untreated, but often remain undetected in primary care. Mild alanine aminotransferase (ALT) elevations (30-100 IU/l) are commonly found and could be associated with viral hepatitis; unfortunately, these findings frequently remain without follow-up. AIM: To determine if and how mild ALT elevation can be used to identify hidden HCV and HBV infection in primary care. DESIGN AND SETTING: Primary care patients referred for liver enzyme testing were selected by a large primary care Diagnostic Centre (Saltro). METHOD: First, 750 anonymous samples were collected in three categories of ALT elevation (30-50 IU/l, 50-70 IU/l, and 70-100 IU/l) and tested for HCV and HBV. Second, the national prevalence of each ALT elevation was estimated by analysing all annual ALT tests performed at Saltro. RESULTS: HCV prevalence was 1.6% and 1.2% in patients with an ALT of 50-70 IU/l and 70-100 IU/l respectively. In patients with an ALT of 30-50 IU/l, HCV prevalence was normal (≤0.1%). HBV prevalence was normal (≤0.4%) in all groups. The estimated number of ALT tests performed nationally each year in primary care was 1.1 million. An ALT of 30-50 IU/l was found in 21.1%, an ALT of 50-70 IU/l in 5.6%, and 2.6% had an ALT of 70-100 IU/l. CONCLUSION: In primary care patients with an ALT level of 50-100 IU/l, HCV prevalence is tenfold the population prevalence, whereas HBV prevalence is not elevated. Therefore, diagnostic follow-up for HCV is indicated in these patients, even when other explanations for ALT elevation are present.
BACKGROUND: Hepatitis C (HCV) and hepatitis B (HBV) virus infection can lead to serious complications if left untreated, but often remain undetected in primary care. Mild alanine aminotransferase (ALT) elevations (30-100 IU/l) are commonly found and could be associated with viral hepatitis; unfortunately, these findings frequently remain without follow-up. AIM: To determine if and how mild ALT elevation can be used to identify hidden HCV and HBV infection in primary care. DESIGN AND SETTING: Primary care patients referred for liver enzyme testing were selected by a large primary care Diagnostic Centre (Saltro). METHOD: First, 750 anonymous samples were collected in three categories of ALT elevation (30-50 IU/l, 50-70 IU/l, and 70-100 IU/l) and tested for HCV and HBV. Second, the national prevalence of each ALT elevation was estimated by analysing all annual ALT tests performed at Saltro. RESULTS: HCV prevalence was 1.6% and 1.2% in patients with an ALT of 50-70 IU/l and 70-100 IU/l respectively. In patients with an ALT of 30-50 IU/l, HCV prevalence was normal (≤0.1%). HBV prevalence was normal (≤0.4%) in all groups. The estimated number of ALT tests performed nationally each year in primary care was 1.1 million. An ALT of 30-50 IU/l was found in 21.1%, an ALT of 50-70 IU/l in 5.6%, and 2.6% had an ALT of 70-100 IU/l. CONCLUSION: In primary care patients with an ALT level of 50-100 IU/l, HCV prevalence is tenfold the population prevalence, whereas HBV prevalence is not elevated. Therefore, diagnostic follow-up for HCV is indicated in these patients, even when other explanations for ALT elevation are present.
Authors: C W Helsper; B A Borkent-Raven; N J de Wit; G A van Essen; M J M Bonten; A I M Hoepelman; M P Janssen; G A de Wit Journal: Epidemiol Infect Date: 2011-02-16 Impact factor: 2.451
Authors: S Slavenburg; F M Verduyn-Lunel; J T Hermsen; W J G Melchers; R H M te Morsche; J P H Drenth Journal: Neth J Med Date: 2008-01 Impact factor: 1.422
Authors: David J McLernon; Peter T Donnan; Stephen Ryder; Paul Roderick; Frank M Sullivan; William Rosenberg; John F Dillon Journal: Fam Pract Date: 2009-05-12 Impact factor: 2.267
Authors: K Ikeda; S Saitoh; Y Suzuki; M Kobayashi; A Tsubota; I Koida; Y Arase; M Fukuda; K Chayama; N Murashima; H Kumada Journal: J Hepatol Date: 1998-06 Impact factor: 25.083
Authors: Andrew D Schreiner; John Bian; Jingwen Zhang; Z Merle Haulsee; Justin Marsden; Valerie Durkalski-Mauldin; Patrick D Mauldin; William P Moran; Don C Rockey Journal: Am J Med Date: 2019-07-29 Impact factor: 4.965
Authors: Kirsty Roberts; John Macleod; Chris Metcalfe; Joanne Simon; Jeremy Horwood; William Hollingworth; Sharon Marlowe; Fiona H Gordon; Peter Muir; Barbara Coleman; Peter Vickerman; Graham I Harrison; Cherry-Ann Waldron; William Irving; Matthew Hickman Journal: Trials Date: 2016-07-29 Impact factor: 2.279
Authors: Rob Bielen; Özgür M Koc; Dana Busschots; Geert Robaeys; Bert Aertgeerts; Bert Vaes; Pavlos Mamouris; Catharina Mathei; Geert Goderis; Frederik Nevens Journal: BMJ Open Date: 2019-05-09 Impact factor: 2.692
Authors: A McLeod; S J Hutchinson; A Weir; S Barclay; J Schofield; C Gillespie Frew; D J Goldberg; M Heydtmann; E Wilson-Davies Journal: Epidemiol Infect Date: 2022-06-27 Impact factor: 4.434